Assessing urinary biomarkers in membranous glomerulonephritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the correlation between urinary biomarkers and serum samples in patients with newly diagnosed membranous glomerulonephritis (MGN). Fifty patients will be recruited and followed for one year, during which serum and urinary biomarkers will be collected every four months and analyzed using ELISA assays. The primary outcome is to determine the correlation of urinary biomarkers with serum markers, while secondary outcomes include their relationship with clinical parameters such as eGFR decline and renal events. This research seeks to establish the clinical utility of urinary biomarkers as a non-invasive alternative to serum samples.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* newly diagnosed biopsy proven primary membranous glomerulonephritis

Exclusion Criteria:

* secondary causes of membranous nephropathy, e.g. lupus nephritis, viral hepatitis B and C and malignancy

Where it's running

• Department of Medicine & Therapeutics, Prince of Wales Hospital
  Shatin, Hong Kong Recruiting

Study contacts

• Study coordinator: Winston WS Fung, MBBS
• Email: fws898@ha.org.hk
• Phone: 35053528

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rituximab plus Cyclosporine for Primary Membranous Nephropathy

  This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT07861204

• HLX79 with rituximab (HLX01) for active glomerulonephritis

  This trial will test whether adding HLX79 at different doses to rituximab (HLX01) helps adults with active membranous nephropathy or lupus nephritis.

  Recruiting Phase 2 Shanghai Henlius Biotech · Beijing and 16 other locations · NCT07038382

• Using Raman Spectroscopy to Diagnose Kidney Diseases

  This study is testing a new way to diagnose kidney diseases by analyzing urine and blood samples from patients with specific kidney conditions to see if it can help identify the diseases more accurately.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT06760845

• Testing ManNAc for treating kidney disease FSGS

  This study is testing if a new oral treatment called ManNAc can help adults with kidney disease FSGS by reducing protein levels in their urine and checking how safe it is over 12 weeks.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06664814

• AI-guided personalized rituximab for membranous nephropathy

  This trial will test whether an AI-guided approach to dosing rituximab improves remission in adults with PLA2R1-positive nephrotic membranous nephropathy.

  Recruiting at 13 sites Phase 3 Centre Hospitalier Universitaire de Nice · Besançon and 13 other locations · NCT06341205

• Long-term outcomes in primary membranous nephropathy

  This project will follow adults with primary membranous nephropathy and nephrotic syndrome to see how their disease and real-world treatments affect long-term kidney outcomes.

  Recruiting Mario Negri Institute for Pharmacological Research · Bergamo, BG and 1 other locations · NCT06242327

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.